Zanamivir for influenza: a public health perspective. Its use will require careful management by GPs.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

1. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments.BMJ (Clinical research ed.) · 2014
   Pooled it
2. Neuraminidase inhibitors for influenza: a review and public health perspective in the aftermath of the 2009 pandemic.Influenza and other respiratory viruses · 2013
   Pooled it
3. Antiviral treatment for viral pneumonia: current drugs and natural compounds.Virology journal · 2025
   Review
4. Response to influenza immunisation during treatment for cancer.Archives of disease in childhood · 2001
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author at 1 institution in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as